HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Clinical trials for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) trials appear
Sign up with your email to follow new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Swiss trial aims to match ovarian cancer patients with better treatments using tumor analysis
Disease control Recruiting nowThis Swiss study is testing whether personalized treatment recommendations can help patients with a hard-to-treat type of ovarian cancer. Researchers will analyze each patient's tumor and have a specialized board suggest treatments, which doctors and patients can then choose to f…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: NA • Sponsor: Swiss GO Trial Group • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Could a breast cancer pill keep ovarian cancer at bay?
Disease control Recruiting nowThis large Phase 3 trial is testing whether adding the drug letrozole to standard maintenance therapy helps prevent ovarian cancer from coming back. It will involve 540 women with ER-positive ovarian, fallopian tube, or peritoneal cancer who have completed initial surgery and che…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: PHASE3 • Sponsor: Swiss GO Trial Group • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
First patients to receive experimental cancer drug in new trial
Disease control Recruiting nowThis is the first human study of an experimental drug called BMS-986463 for people with advanced ovarian, uterine, or lung cancers. The main goal is to find safe dose levels and see how the body processes the drug. Researchers will enroll about 240 participants to monitor side ef…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC